A Survey of Antiemetic Use in Children With Cancer

Hoff, Jack van; Hockenberry-Eaton, Marilyn; Patterson, K.W.; Hutter, John J.

doi:10.1001/archpedi.1991.02160070069024

Cited by 7 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phenothiazines, butyrophenones, antihistamines, corticosteroids, and cannabinoids all confer antiemetic properties and as such have been and still are used alone or in combination in the prevention and management of chemotherapy-induced nausea and vomiting [1,2]. Until recently, the dopamine receptor antagonist metoclopramide was considered the cornerstone of antiemetic treatment.…”

Section: Introductionmentioning

confidence: 99%

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy

Coppes

Lau

Ingram

et al. 1999

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Background Nausea and vomiting are among the most unpleasant adverse side effects of cancer therapy. Procedure An open‐label dose‐escalation study was conducted to assess the appropriate intravenous dose of dolasetron for pediatric patients undergoing chemotherapy. Patients received dolasetron in single intravenous doses of 0.6 (n = 10), 1.2 (n = 12), 1.8 (n = 12), or 2.4 (n = 12) mg/kg 30 min before receiving emetogenic chemotherapy. Pharmacokinetic parameters were evaluated at each dose level and efficacy was evaluated over the first 24 hr following the administration of dolasetron. Results A complete response was achieved in 10% of patients given 0.6 mg/kg, 25% of patients given 1.2 mg/kg, 67% of patients given 1.8 mg/kg, and 33% of patients given 2.4 mg/kg. Peak plasma concentrations (Cmax) were observed between 0.33 and 0.75 hr following dolasetron infusion. Cmax and area under plasma concentration‐time (AUC) increased with larger doses of dolasetron, while terminal disposition half‐life (t1/2) and apparent clearance (Clapp) were not significantly changed with respect to dose. For 1.8‐mg/kg dolasetron, the t1/2 was 4.98 hr and the maximum plasma concentration (tmax) 0.47 hr. Adverse events were mild to moderate. No serious events occurred. Conclusions. This study suggests that a single intravenous dose of 1.8 mg/kg is the optimum single intravenous dose for controlling chemotherapy‐induced emesis in pediatric patients. Med. Pediatr. Oncol. 33:99–105, 1999. © 1999 Wiley‐Liss, Inc.

show abstract

Section: Introductionmentioning

confidence: 99%

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy

Coppes

Lau

Ingram

et al. 1999

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

show abstract

The antiemetic activity of granisetron against cytostatic-treatment-induced emesis in 10- to 13-week-old ferrets

Marr

Davey

Boyle

et al. 1994

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

The antiemetic activity of granisetron was examined in ferrets aged 10-13 weeks. Emesis was induced by exposure to either whole-body X-irradiation (50 Gy over 10.4 min) or cyclophosphamide (80 mg/kg i.v.) plus doxorubicin (6 mg/kg i.v.). Following exposure to whole-body X-irradiation, the young ferrets vomited with a similar latency to vomit and severity of emesis to that shown by adult animals. Granisetron (0.5 mg/kg i.v.) significantly reduced (P < or = 0.05) the number of vomits and retches and two out of four animals were completely protected. Following injection of cyclophosphamide and doxorubicin, the young ferrets showed a reduced emetic response compared to adult animals. Following a dose of granisetron (0.5 mg/kg i.v.), only one out of four ferrets vomited compared to four out of four in the control group. Further experiments showed that cisplatin (12.5 mg/kg i.v.) was unable to induce vomiting in the young ferret (n = 2). Granisetron (0.5 mg/kg i.v.) was well tolerated by the young ferret and was able to reduce significantly or completely abolish emesis induced by cytostatic treatment. The data support the use of granisetron in pediatric patients and clinical trials are currently underway in this patient population.

show abstract

Creating a Novel Structure for Nursing Research in a Cooperative Clinical Trials Group: The Children’s Oncology Group Experience

Ruccione

Hinds²,

Wallace³

et al. 2005

Seminars in Oncology Nursing

View full text Add to dashboard Cite

A Survey of Antiemetic Use in Children With Cancer

Cited by 7 publications

References 20 publications

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy

The antiemetic activity of granisetron against cytostatic-treatment-induced emesis in 10- to 13-week-old ferrets

Creating a Novel Structure for Nursing Research in a Cooperative Clinical Trials Group: The Children’s Oncology Group Experience

Contact Info

Product

Resources

About